NeoPharm reiterated by JMP at buy

NeoPharm Inc. was reiterated by JMP Securities analyst Charles Duncan at a buy rating with a price target on the stock of $19 per share following news that the FDA approved an amendment to the company's Special Protocol Assessment for the phase III trial of IL13-PE38 to include an interim efficacy analysis of data when 160 deaths are reached. JMP sees this development as a strong affirmation that effective treatment of brain cancer remains a clear unmet medical need and that a BLA filing could move up by 6-12 months to mid 2006. NeoPharm shares Thursday were up $0.83, or 6.57%, at $13.46 on volume of 490,074 shares versus the three-month running average of 181,857 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.